Loading patent…
OwnerMichael D. Dan, Mansoor Salehinventors
Estimating the term…
The present invention relates to monoclonal antibody 4B5 and antigen binding fragments that specifically bind to the antibodies specific for GD2. Also disclosed are polynucleotide and polypeptide derivatives based on 4B5, including single chain V region molecules and fusion proteins, and various pharmaceutical compositions. When administered to an individual, the 4B5 antibody is effective in diagnosing, and/or treating neoplasias. The invention further provides methods for treating a neoplastic disease, particularly melanoma, neuroblastoma, glioma, soft tissue sarcoma, and lung carcinomas. Patients who are in remission as a result of traditional modes of cancer therapy can be treated with a composition of this invention in hopes of reducing the risk of recurrence. Patients can also be treated concurrently with the antibodies and traditional anti-neoplastic agents.
A substantially isolated polynucleotide sequence that encodes an antigen binding fragment of an antibody, having the amino acid sequences of SEQ ID NOS:3 and 6.
A substantially isolated polynucleotide sequence that encodes at least five consecutive amino acid residues of SEQ ID NOS:3 or 6.
An isolated polynucleotide comprising a region of at least 20 consecutive nucleotides that is capable of selectively forming a stable duplex with a polynucleotide consisting of SEQ ID NO:2 or 5.
An isolated polynucleotide comprising a region of at least 20 consecutive nucleotides that is capable of selectively forming a stable duplex with a polynucleotide consisting of SEQ ID NO:1 or 4.
A composition comprising an antigen binding fragment of an antibody having the amino acid sequence of SEQ ID NO:3 and a L chain V region having the amino acid sequence of SEQ ID NO:6.
A polypeptide comprising at least five consecutive amino acid residues of SEQ ID NOS:3 or 6.
A composition comprising substantially purified recombinant 4B5-antigen, comprising a H chain V region having the amino acid sequence of SEQ ID NO:3 and a L chain V region having the amino acid sequence of SEQ ID NO:6.
Dependencies are inferred from the claim text.